Company
Headquarters: Irvine, CA, United States
Employees: 49
CEO: Mr. Joseph Michael Burnett
$492.4 Million
USD as of Jan. 1, 2025
Company | Market Cap (USD) |
---|---|
Abbott | $213.72 B |
Stryker | $150.01 B |
Boston Scientific Corporation | $149.80 B |
Medtronic | $114.44 B |
Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $47.37 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Last Financial Reports Date | Dec. 31, 2023 |
Revenue TTM | $24.0 M |
EBITDA | $-21,820,000 |
Gross Profit TTM | $13.6 M |
Profit Margin | -92.21% |
Operating Margin | -69.10% |
Quarterly Revenue Growth | 31.60% |
ClearPoint Neuro, Inc. has the following listings and related stock indices.
Stock: NASDAQ: CLPT wb_incandescent